Immuron Ltd. IMRN 深 滬
等待開盤 09-06 09:30:00 美东时间
1.858
-0.032
-1.69%
華盛通- 最 高1.89
- 今 開1.87
- 成交量 1.13万股
- 最 低 1.79
- 昨 收 1.89
- 總市值 1064.37万
- 52周最高 2.867
- 市盈率 靜 --
- 換手率 0.20%
- 52周最低 1.50
- 委 比 26.98%
- 總股本 572.86万
- 歷史最高 28.99
- 量 比 0.26
- 振 幅 5.29%
- 歷史最低 1.39
- 每 手 1
- 風險率 0.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immuron partners with InvestorHub
Immunot Limited has partnered with InvestorHub to launch an interactive investor hub, enhancing communication with shareholders and investors. The platform will feature regular updates, including videos, educational materials, and research. CEO Steven Lydeamore highlighted upcoming milestones: FDA submission and approval of IMM-529 IND and clinical trial results for Travelan®. The company focuses on developing orally administered antibodies for i...
08-27 02:29
Immuron Enhances Investor Engagement with New Interactive Hub
Immuron Limited ( ($AU:IMC) ) has issued an announcement. Immuron Limited has p...
08-26 13:57
Immuron CEO to Present at Coffee Microcaps Conference
Immuron Limited ( ($AU:IMC) ) has issued an announcement. Immuron Limited annou...
07-25 08:57
Why Interactive Brokers Group Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
Shares of Interactive Brokers Group, Inc. (NASDAQ:IBKR) rose sharply in pre-mar...
07-18 18:34
Immuron Says 2025 Sales Growth Of 49% For Travelan Exceeded Projection
GlobalAnnual sales AUD$7.3 million up 49% on prior yearJune 2025 Quarter AUD$2.0 million up 55% on prior yearAustralia Annual sales AUD$5.2 million up 40% on prior yearJune 2025 Quarter AUD$1.5 million up 58% on
07-17 18:07
Immuron - FY25 global sales exceed projection, up 49% on prior year
Immuron Limited reported FY25 sales growth of 49% to $7.3M AUD, driven by strong performance in Australia (40% growth) and North America (76% growth). Travelan® sales exceeded projections, benefiting from increased consumer engagement and targeted marketing efforts, particularly on Amazon in the U.S. and expanding distribution in Canada. --- **总结内容：** Immuron Limited FY25销售额增长49%至730万澳元，澳大利亚市场增长40%，北美市场增长76%。Travelan®销售额超出预期，得益于消费者参与度提高和针对性营销，...
07-17 10:00
Immuron Limited Issues 877,440 New Shares Without Disclosure
An announcement from Immuron Limited ( ($AU:IMC) ) is now available. Immuron Li...
07-17 09:08
BNYMC Increases Stake in Immuron Limited
Immuron Limited ( ($AU:IMC) ) has shared an announcement. Immuron Limited has a...
07-01 07:08
Immuron Letter to Shareholders: Projects Update
Immuron Limited reported record sales of $7 million for FY2025, up from $4.9 million last year. Key updates include: Travelan® clinical study results expected in October 2025; IMM-529 IND submission to FDA in August 2025 forClostridioides difficile infection; ProIBS® launch in Australia planned for January 2026; and IMM-986 pre-clinical results anticipated in August 2025 for Vancomycin-resistant enterococci. Sales momentum continued through Easte...
05-30 10:00
Immuron Limited Poised for Record Sales and Clinical Advancements
An announcement from Immuron Limited ( ($AU:IMC) ) is now available. Immuron Li...
05-30 08:49
